We are committed to developing the world's first 'off-the-shelf' cell therapy to destroy all solid tumours, irrespective of strain or mutation. We are achieving this by bringing to market a first in class allogeneic innate cell therapy called Neutrophil Only Leukocyte Infusion Therapy (N-LIfT). 


Our first Mission is to show remission in high unmet need solid tumours by 2023,

with an initial focus on pancreatic cancer.